| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14 |
| filingDate |
2014-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2017-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-105683195-B |
| titleOfInvention |
The compound of quinoline substitution |
| abstract |
The purpose to be realized of the present invention is to provide the noval chemical compound with EGFR inhibitory action and cell growth inhibition, and can be used for the medicine of prevention and/or treating cancer based on EGFR inhibitory action.The present invention provides the compound or its salt represented by lower formula (I) |
| priorityDate |
2013-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |